Hip Dysplasia: Understanding a Very Misunderstood Puppy Abnormality
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Pain Management E-Book
VetEdPlus E-BOOK RESOURCES Pain Management E-Book WHAT’S INSIDE Gabapentin and Amantadine for Chronic Pain: Is Your Dose Right? Grapiprant for Control of Osteoarthritis Pain in Dogs Use of Acupuncture for Pain Management Regional Anesthesia for the Dentistry and Oral Surgery Patient A SUPPLEMENT TO Laser Therapy for Treatment of Joint Disease in Dogs and Cats Manipulative Therapies for Hip and Back Hypomobility in Dogs E-BOOK PEER REVIEWED CONTINUING EDUCATION Gabapentin and Amantadine for Chronic Pain: Is Your Dose Right? Tamara Grubb, DVM, PhD, DACVAA Associate Professor, Anesthesia and Analgesia Washington State University College of Veterinary Medicine Pain is not always a bad thing, and all pain is not Untreated or undertreated pain can cause myriad the same. Acute (protective) pain differs from adverse effects, including but not limited to chronic (maladaptive) pain in terms of function insomnia, anorexia, immunosuppression, and treatment. This article describes the types of cachexia, delayed wound healing, increased pain pain, the reasons why chronic pain can be sensation, hypertension, and behavior changes difficult to treat, and the use of gabapentin and that can lead to changes in the human–animal amantadine for treatment of chronic pain. bond.2 Hence, we administer analgesic drugs to patients with acute pain, not to eliminate the protective portion but to control the pain ACUTE PAIN beyond that needed for protection (i.e., the pain Acute pain in response to tissue damage is often that negatively affects normal physiologic called protective pain because it causes the processes and healing). This latter type of pain patient to withdraw tissue that is being damaged decreases quality of life without providing any to protect it from further injury (e.g., a dog adaptive protective mechanisms and is thus withdrawing a paw after it steps on something called maladaptive pain. -
Canine Hip Dysplasia - by Patricia Long October, 2001
Canine Hip Dysplasia - by Patricia Long October, 2001 Edited by Melissa Zebley, DVM Contributions by: Sue Bacig, Brenda Briggs, Sue Brightman, Cathy Burlile, Janice Cagwin, Steve Dudley, Lisa Ebnet, Sue German, Kathy Maher, Ruth Reynolds, Rose Tierney, Sue Sanvido, Doug Smith Much has been written on hip dysplasia (HD), and this article is simply an attempt to summarize much of that information. For a more in-depth examination of HD, I urge you to read the articles by Susan Thorpe-Vargas and John Cargill which can be found on http://workingdogs.com/ Prevention - the ounce worth more than a pound Breeders have several methods of trying to minimize the risk of HD: OFA, GDC, PennHIP. But these registries are only able to identify some dogs that may have HD. They are not able to identify the dogs that carry the genes for HD. It is important to understand that no matter how many generations there are in the pedigree with hips rated clear, all this can do is to minimize the risk of HD - it can't eliminate it. HD is a polygenetic multifactorial condition, which means that we still don't know exactly what causes it. But without the genes for it, a dog won't get it without some other event such as an injury. What is HD? The hip joint is a clever device, the classic ball and socket joint. Properly constructed, the top of the thigh bone, or femoral head, is the ball that fits into the socket, or acetabulum, in the pelvis. But in dogs, as in humans, this joint does not always develop properly. -
British Veterinary Association / Kennel Club Hip Dysplasia Scheme
British Veterinary Association / Kennel Club Hip Dysplasia Scheme Breed Specific Statistics – 1 January 2001 to 31 December 2016 Hip scores should be considered along with other criteria as part of a responsible breeding programme, and it is recommended that breeders choose breeding stock with hip scores around and ideally below the breed median score, depending on the level of HD in the breed. HD status of parents, siblings and progeny for Kennel Club registered dogs should also be considered, and these together with a three generation Health Test Pedigree may be downloaded via the Health Test Results Finder, available on the Kennel Club’s online health tool Mate Select (www.mateselect.org.uk). In addition, estimated breeding values (EBVs) are available for breeds in which a significant number of dogs have been graded, via the same link. For further advice on the interpretation and use of hip scores see www.bva.co.uk/chs The breed median score is the score of the ‘average’ dog in that breed (i.e. an equal number of dogs in that breed have better and worse scores). No. 15 year No. 15 year 5 year 5 year Breed score in Breed score in Range Median Median Range Median Median 15 years 15 years Affenpinscher 40 8 – 90 13 14 Beagle 62 8 - 71 16 17 Afghan Hound 18 0 – 73 8.5 27 Bearded Collie 1511 0 – 70 9 9 Airedale Terrier 933 4 – 72 11 10 Beauceron 42 2 – 23 10 10 Akita 1029 0 – 91 7 7 Belgian Shepherd 249 0 – 37 8 8 Dog (Groenendael) Alaskan Malamute 1248 0 – 78 10 10 Belgian Shepherd 16 5 - 16 10 14 Dog (Laekenois) Anatolian 63 3 – 67 9 -
A Review of the Effects of Pain and Analgesia on Immune System Function and Inflammation: Relevance for Preclinical Studies
Comparative Medicine Vol 69, No 6 Copyright 2019 December 2019 by the American Association for Laboratory Animal Science Pages 520–534 Overview A Review of the Effects of Pain and Analgesia on Immune System Function and Inflammation: Relevance for Preclinical Studies George J DeMarco1* and Elizabeth A Nunamaker2 One of the most significant challenges facing investigators, laboratory animal veterinarians, and IACUCs, is how to bal- ance appropriate analgesic use, animal welfare, and analgesic impact on experimental results. This is particularly true for in vivo studies on immune system function and inflammatory disease. Often times the effects of analgesic drugs on a particu- lar immune function or model are incomplete or don’t exist. Further complicating the picture is evidence of the very tight integration and bidirectional functionality between the immune system and branches of the nervous system involved in nociception and pain. These relationships have advanced the concept of understanding pain as a protective neuroimmune function and recognizing pathologic pain as a neuroimmune disease. This review strives to summarize extant literature on the effects of pain and analgesia on immune system function and inflammation in the context of preclinical in vivo studies. The authors hope this work will help to guide selection of analgesics for preclinical studies of inflammatory disease and immune system function. Abbreviations and acronyms: CB,Endocannabinoid receptor; CD,Crohn disease; CFA, Complete Freund adjuvant; CGRP,Calcitonin gene-related -
Grapiprant: an EP4 Prostaglandin Receptor Antagonist and Novel Therapy for Pain and Inflammation
DOI: 10.1002/vms3.13 Review Grapiprant: an EP4 prostaglandin receptor antagonist and novel therapy for pain and inflammation † Kristin Kirkby Shaw , Lesley C. Rausch-Derra* and Linda Rhodes* † *Aratana Therapeutics, Inc., Kansas City, Kansas, USA and Animal Surgical Clinic of Seattle, Seattle, Washington, USA Abstract There are five active prostanoid metabolites of arachidonic acid (AA) that have widespread and varied physio- logic functions throughout the body, including regulation of gastrointestinal mucosal blood flow, renal haemo- dynamics and primary haemostasis. Each prostanoid has at least one distinct receptor that mediates its action. Prostaglandin E2 (PGE2) is a prostanoid that serves important homeostatic functions, yet is also responsible for regulating pain and inflammation. PGE2 binds to four receptors, of which one, the EP4 receptor, is primar- ily responsible for the pain and inflammation associated with osteoarthritis (OA). The deleterious and patho- logic actions of PGE2 are inhibited in varying degrees by steroids, aspirin and cyclo-oxygenase inhibiting NSAIDs; however, administration of these drugs causes decreased production of PGE2, thereby decreasing or eliminating the homeostatic functions of the molecule. By inhibiting just the EP4 receptor, the homeostatic function of PGE2 is better maintained. This manuscript will introduce a new class of pharmaceuticals known as the piprant class. Piprants are prostaglandin receptor antagonists (PRA). This article will include basic physiol- ogy of AA, prostanoids and piprants, will review available evidence for the relevance of EP4 PRAs in rodent models of pain and inflammation, and will reference available data for an EP4 PRA in dogs and cats. Piprants are currently in development for veterinary patients and the purpose of this manuscript is to introduce veteri- narians to the class of drugs, with emphasis on an EP4 PRA and its potential role in the control of pain and inflammation associated with OA in dogs and cats. -
GALLIPRANT; INN: Grapiprant
9 November 2017 EMA/747932/2017 Veterinary Medicines Division Committee for Medicinal Products for Veterinary Use CVMP assessment report for GALLIPRANT (EMEA/V/C/004222/0000) International non-proprietary name: grapiprant Assessment report as adopted by the CVMP with all information of a commercially confidential nature deleted. 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. Introduction ........................................................................................................................... 4 Scientific advice ........................................................................................................................ 4 MUMS/limited market status ...................................................................................................... 4 Part 1 - Administrative particulars ......................................................................................... 5 Detailed description of the pharmacovigilance system ................................................................... 5 Manufacturing authorisations and inspection status ....................................................................... 5 Overall conclusions on administrative particulars ......................................................................... -
Cartilage Borderline
Prevalence of High-Grade Cartilage Defects in Patients With Borderline Dysplasia With Femoroacetabular Impingement: A Comparative Cohort Study Ioanna K. Bolia, M.D., M.S., Ph.D., Karen K. Briggs, M.P.H., Renato Locks, M.D., Jorge Chahla, M.D., Hajime Utsunomiya, M.D., Ph.D., and Marc J. Philippon, M.D. Purpose: To compare the prevalence, size, and location of Outerbridge grade III and IV cartilage defects on the femoral head and acetabulum between patients with borderline acetabular dysplasia and patients with non-borderline dysplasia who underwent hip arthroscopy for femoroacetabular impingement (FAI). Methods: Patients aged 18 years or older who underwent primary hip arthroscopy for correction of FAI and labral repair from November 2005 to April 2016 were included. We excluded patients with previous hip surgery, a radiographic hip joint space of 2 mm or less, and/or a lateral center-edge angle (LCEA) of less than 20 or greater than 40. The study patients were divided into 2 groups based on the LCEA on the anteroposterior pelvic radiograph: Patients with an LCEA between 20 and 25 were included in the borderline group, and patients with an LCEA between 25 and 40 were included in the non-borderline group. The prevalence, size, and location of Outerbridge grade III and IV chondral lesions on the femoral head and acetabulum were recorded intraoperatively. Comparisons between groups were performed with the Mann-Whitney U test for nonpara- metric testing and the t test for data that were normally distributed. Data were analyzed to calculate odds ratios associated with the various factors. -
New Ideas, New Voices”
American Academy of Veterinary Pharmacology and Therapeutics 21th Biennial Symposium “New Ideas, New Voices” Overland Park Convention Center, Overland Park, Kansas August 23-26, 2019 1 TABLE OF CONTENTS Scheduled Program ....................................................................................................................................... 3 SPONSORS ................................................................................................................................................... 6 Tom Powers Memorial Keynote Address .................................................................................................. 9 SESSION 1: New Ideas, New Voices ........................................................................................................ 14 SESSION 2: Graduate Student Presentations ......................................................................................... 33 Oral Presentations.................................................................................................................................. 33 Poster Abstracts ..................................................................................................................................... 34 SESSION 3: Antimicrobials and Diagnostic Laboratories .................................................................... 52 SESSION 4: Graduate skills and training ............................................................................................... 64 SESSION 5: Start-ups and New Business Ideas ..................................................................................... -
Galliprant (Grapiprant Tablets) for Oral Use in Dogs Only 20 Mg, 60 Mg
GALLIPRANT- grapiprant tablet Elanco US Inc. ---------- Galliprant® (grapiprant tablets) For oral use in dogs only 20 mg, 60 mg and 100 mg flavored tablets A prostaglandin E2 (PGE2) EP4 receptor antagonist; a non-cyclooxygenase inhibiting, non- steroidal anti-inflammatory drug Caution: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. Description: GALLIPRANT (grapiprant tablets) is a prostaglandin E2 (PGE2) EP4 receptor antagonist; a non- cyclooxygenase (COX) inhibiting, non-steroidal anti-inflammatory drug (NSAID) in the piprant class. GALLIPRANT is a flavored, oval, biconvex, beige to brown in color, scored tablet debossed with a “G” that contains grapiprant and desiccated pork liver as the flavoring agent. The molecular weight of grapiprant is 491.61 Daltons. The empirical formula is C26H29N5O3S. Grapiprant is N-[[[2-[4-(2-Ethyl-4,6-dimethyl-1H-imidazo[4,5-c] pyridin-1- yl)phenyl]ethyl]amino]carbonyl]-4 methylbenzenesulfonamide. The structural formula is: Indication: GALLIPRANT (grapiprant tablets) is indicated for the control of pain and inflammation associated with osteoarthritis in dogs. Dosage and Administration: Always provide “Information for Dog Owners” Sheet with prescription. Use the lowest effective dose for the shortest duration consistent with individual response. The dose of GALLIPRANT (grapiprant tablets) is 0.9 mg/lb (2 mg/kg) once daily. Only the 20 mg and 60 mg tablets of GALLIPRANT are scored. The dosage should be calculated in half tablet increments. Dogs less than 8 lbs. (3.6 kgs) cannot be accurately dosed. Dosing Chart Dose Weight in pounds Weight in 20 mg tablet 60 mg tablet 100 mg tablet kilograms 8-15 3.6-6.8 0.5 0.9 mg/lb (2 15.1-30 6.9-13.6 1 mg/kg) once 30.1-45 13.7-20.4 0.5 daily 45.1-75 20.5-34 1 75.1-150 34.1-68 1 The 100 mg tablet is not scored and should not be broken in half. -
PERIACETABULAR OSTEOTOMY (PAO) All Information Here Is General in Nature and Needs to Be Tailored to Your Circumstances
PERIACETABULAR OSTEOTOMY (PAO) All information here is general in nature and needs to be tailored to your circumstances Overview PAO surgery is a hip preservation surgery performed to correct a deformity in the acetabulum (hip socket) such as acetabular dysplasia. If this condition remains untreated, secondary arthritis commonly develops. Therefore, in order to relieve symptoms and improve the prognosis of the hip, this surgery is done to correct the bony anatomy and help normalize the load across the joint. “Periacetabular” means around the acetabulum (hip socket). “Osteotomy” means to cut bone. Therefore, periacetabular osteotomy means to cut the bone around the acetabulum and reposition the hip socket. The PAO is a very effective procedure for the treatment of symptomatic acetabular dysplasia. Mr Slattery is trained in a minimally invasive form of periacetabular osteotomy using a groin crease incision. An incision is made across the front of the hip joint to allow exposure of the hip and surrounding pelvis. Then specialised instruments are used with X-ray vision to perform controlled cuts of the pelvis and free the acetabulum from the pelvis. The acetabulum is repositioned and fixed in the new position with three or four screws after further checks with X-ray. This is a highly specialised procedure which is done by only a few surgeons worldwide. It was pioneered in Switzerland with Prof. Ganz, which is where Dr Slattery undertook sub-specialist fellowship training to learn the art of this procedure. A pelvic model is shown and demonstrates the bony cuts and repositioning of the acetabulum. The gaps between the repositioned bone fill in with new bone, just like the healing of a fracture. -
Hip Dysplasia Scheme Breed Specific Statistics 2019
Hip Dysplasia Scheme Breed Specific Statistics 2019 The below table outlines the median hip score for each breed screened under the CHS Hip Dysplasia Scheme. The breed median score is the ‘middle’ score for all dogs’ in that breed (i.e. an equal number of dogs in that breed have scored higher or lower than the median score). Hip scores should be considered along with other criteria as part of responsible breeding programme. It is recommended that breeders choose breeding stock with hips scores around, and ideally below, the 5-year breed median score. By representing dogs scored in the last 15 years, a more accurate reflection of each breed’s current state of health and improvement is given. The 5-year median here refers to dogs scored between 1st January 2015 and 31st December 2019. Hip dysplasia status of the parents, siblings and progeny for Kennel Club registered dogs should also be considered, and these together with a three generation Health Test Pedigree may be downloaded via the Health Test Results Finder, available on the Kennel Club's online health tool Mate Select. In addition, estimated breeding values (EBVs) are available for breeds in which a significant number of breeds have been scored, via the same link. Tested 15 15 years 5 years Breed Tested 2019 years Mean Min Max Median Mean Median Affenpinscher 40 0 17.9 8.0 90.0 13.0 23.8 23.0 Afghan Hound 85 33 12.3 4.0 73.0 10.0 12.6 10.0 Airedale Terrier 910 58 13.9 4.0 77.0 11.0 13.8 11.0 Akita 883 27 7.7 0.0 58.0 6.0 8.0 7.0 Alaskan Malamute 1242 25 11.7 0.0 78.0 10.0 10.1 9.0 -
Just How Bad Is Hip Dysplasia
Facts about Hip Dysplasia For years this word has been passed around as something that Common breeds affected with is seen occasionally in large breed dogs, but what is hip dysplasia and hip dysplasia: what can be done to prevent it? Hip dysplasia is literally arthritis of 1) English Bulldog 74% bad the hip joints. Hip dysplasia is considered to be an inherited disease 2) Pug 63% bad since hip conformation is passed down from the dam and sire to the 3) Dogue de Bordeux 56% bad puppies. The hip joint is a ball and socket joint, so the more of the 4) Neopolitan Mastiff 49% bad ball that is covered by the socket, the less likely the dog is to develop 5) St. Bernard 47% bad hip dysplasia. Evaluating hip joint conformation is very difficult to 6) Cane Corso 40% bad do without doing x-rays. Manual palpation of the hip joint can 7) Basset 36% bad be done but many poorly conformed hip joints may feel “tight” at 8) French Bulldog 34% bad 8-12 weeks of age. There have been many discussions about the 9) American Bulldog 33% bad hereditary aspect of hip dysplasia and if any other factors contribute to 10) Newfoundland 26% bad hip dysplasia. Hip dysplasia can be affected by the body condition of the dog. Purina foods did a study with a litter of Labradors in which they split up a litter of puppies and kept ½ the litter in an obese condition (>5 body condition score) and the other ½ of the litter in good lean body condition (<5 body condition score).